Suppr超能文献

尽管已进行充分的β受体阻滞剂治疗,但对于心绞痛患者,氨氯地平联合阿替洛尔的价值。

Value of the addition of amlodipine to atenolol in patients with angina pectoris despite adequate beta blockade.

作者信息

Dunselman P H, van Kempen L H, Bouwens L H, Holwerda K J, Herweijer A H, Bernink P J

机构信息

Department of Clinical Pharmacology, University of Groningen, The Netherlands.

出版信息

Am J Cardiol. 1998 Jan 15;81(2):128-32. doi: 10.1016/s0002-9149(97)00877-1.

Abstract

Anginal patients who remain symptomatic despite optimally dosed beta blockade may also be given dihydropyridine calcium antagonists. This treatment regimen was examined in a double-blind parallel, randomized, controlled study in 147 patients with angina and positive bicycle exercise tests despite optimal beta blockade with atenolol (heart rate at rest <60 beats/min). Patients were randomized to atenolol and/or placebo (control), and atenolol and/or amlodipine. The main outcome measurement was exercise tolerance after 8 weeks compared with baseline. After 8 weeks, no significant differences in time to 0.1-mV ST-segment depression, time to chest pain, and time to end of exercise were observed. The number of patients with chest pain during exercise decreased significantly in the amlodipine group (p = 0.04 vs controls). The subgroup of patients with an early (<6 minutes) onset of chest pain at baseline showed a significant increase in time to chest pain after amlodipine (p = 0.0001 vs controls). In the amlodipine group, ST depression and rate-pressure product at submaximum comparable workload decreased to 0.4 mm (0.56) (p = 0.03 vs controls) and 1.223 (2.652) beats/ min x mm Hg (p = 0.01 vs controls). The number of patients in each group with adverse events was not different. The addition of amlodipine to the treatment of patients with myocardial ischemia, despite optimal beta blockade, is well tolerated and may lead to improvement in symptomatic anginal patients, who have a rapid onset of exercise-induced ischemia.

摘要

尽管使用了最佳剂量的β受体阻滞剂仍有症状的心绞痛患者,也可给予二氢吡啶类钙拮抗剂。在一项双盲平行、随机、对照研究中,对147例心绞痛患者进行了这种治疗方案的研究,这些患者尽管使用阿替洛尔进行了最佳的β受体阻滞剂治疗(静息心率<60次/分钟),但自行车运动试验结果仍为阳性。患者被随机分为阿替洛尔和/或安慰剂(对照组),以及阿替洛尔和/或氨氯地平组。主要结局指标是与基线相比8周后的运动耐量。8周后,在达到0.1-mV ST段压低的时间、出现胸痛的时间和运动结束的时间方面未观察到显著差异。氨氯地平组运动期间胸痛患者的数量显著减少(与对照组相比p = 0.04)。基线时胸痛发作较早(<6分钟)的患者亚组,在使用氨氯地平后出现胸痛的时间显著增加(与对照组相比p = 0.0001)。在氨氯地平组中,次最大可比工作量时的ST段压低和心率-血压乘积分别降至0.4 mm(0.56)(与对照组相比p = 0.03)和1.223(2.652)次/分钟×mmHg(与对照组相比p = 0.01)。每组发生不良事件的患者数量没有差异。对于心肌缺血患者,尽管使用了最佳的β受体阻滞剂治疗,但加用氨氯地平耐受性良好,可能会改善运动诱发缺血发作迅速的症状性心绞痛患者的病情。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验